Patients with cancer and suppressed immune systems are at risk of severe COVID-19 infection when treated with systemic therapies, especially immunotherapies.

TOP INSIGHT
Immunocompromised patients with cancer should be especially careful about avoiding COVID-19 and, if necessary, should be aggressive about getting treatment.
The findings suggest that immunocompromised patients with cancer should be especially careful about avoiding COVID and, if they do contract the disease, should be aggressive about getting treatment.
COVID-19: Why is it Mild for Some, Deadly for Others?
Patients whose immune systems have not been suppressed, however, can safely receive cancer therapies – immunotherapies or drug agents – without being at additional risk from COVID-19.This study was done to determine which patients are most at risk for adverse outcomes. They looked specifically at patients treated with immunotherapies, which stimulate the immune system to fight cancer, and those treated with other drugs that suppress the immune system.
Drawing on the COVID-19 and Cancer Consortium (CCC19) registry, researchers analyzed data from 12,046 patients with COVID-19 who had a current or past diagnosis of cancer, making it one of the largest data sets to date analyzed about patients with COVID-19 and cancer.
The analysis examined whether a suppressed immune system or treatment with immunotherapy was associated with worse outcomes from COVID-19 – with hospitalization or death from the disease, and with "cytokine storm," a potentially dangerous overreaction of the immune system to infection.
Patients at high risk for severe COVID should take steps to keep that risk as low as possible: wearing a mask, avoiding crowded places, and staying current with vaccines and boosters.
When counseling patients about treatment, it's important that we discuss the benefits and risks of treatment with systemic therapies for COVID-19.
Source-Eurekalert
MEDINDIA




Email










